We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Explore Intra-tumor Heterogeneity and Prognostic Value of Postoperative Blood ctDNA of ⅡA - ⅢA Stage Non-squamous NSCLC Based on the Capture-based Sequencing and UMI Technology of Burning Rock

This study is currently recruiting participants.
Verified November 2017 by Hao Long, Sun Yat-sen University
Sponsor:
ClinicalTrials.gov Identifier:
NCT03337711
First Posted: November 9, 2017
Last Update Posted: November 9, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Hao Long, Sun Yat-sen University
  Purpose
The study will collect 100 ⅡA - ⅢA stage non-squamous NSCLC tumor tissue and blood specimens (Include: (1) tissue by operation: 3 specimens from different regions of each patient; (2) Blood: preoperative blood (within one week), postoperative blood (3-4 weeks after operation (before adjuvant chemotherapy), 20 weeks after operation (1 month after adjuvant chemotherapy), 1 year after operation). Capture-based sequencing(168 genes panel +UMI) will performed. All patients are recommended for "pemetrexed combined platinum" adjuvant chemotherapy for 4 cycles(Moderate-dose Chemotherapy) 3-4 weeks after operation. The clinical data should be collected until disease progression. The relationship of postoperative ctDNA and recurrence defined by clinical imaging will be analyzed, as well as the correlation of tissue and postoperative blood NGS results.

Condition
Non-small Cell Lung Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Open Multicenter Clinical Study to Explore Intra-tumor Heterogeneity and Prognostic Value of Postoperative Blood ctDNA of ⅡA - ⅢA Stage Non-squamous NSCLC Based on the Capture-based Sequencing and UMI (Unique Molecular Identifier) Technology of Burning Rock

Resource links provided by NLM:


Further study details as provided by Hao Long, Sun Yat-sen University:

Primary Outcome Measures:
  • recurrence or metastasis [ Time Frame: two years after the last patient entered the study ]
    The patient was diagnosed as recurrence or metastasis according to the computed tomography (CT) scan


Biospecimen Retention:   Samples With DNA
The relationship of postoperative ctDNA and recurrence defined by clinical imaging will be analyzed, as well as the correlation of tissue and postoperative blood NGS results.

Estimated Enrollment: 100
Actual Study Start Date: May 24, 2017
Estimated Study Completion Date: May 31, 2020
Estimated Primary Completion Date: May 31, 2020 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with postoperative pathologic staging diagnosis of ⅡA to ⅢA non-squamous NSCLC period
Criteria

Inclusion Criteria:

  1. Received radical surgical treatment and postoperative pathological had pointed out non-squamous NSCLC;
  2. Patients with postoperative pathologic staging diagnosis of Ⅱ A - Ⅲ A period (AJCC TNM staging (version 8));
  3. Female or male Age ≥ 18 years and ≤ 75;
  4. Did not receive any of the anti-tumor treatment for current disease, such as radiation therapy, chemotherapy, or molecular target, etc;
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0/1;
  6. The expect survival time is more than 6 months;
  7. Screening laboratory results:

(1) Hematological:Absolute Neutrophil Count (ANC) ≥ 1500 K/mm^3 (without use of G-CSF 4 weeks prior to enrollment);Hemoglobin (Hgb) ≥ 9 g/dL (transfusions allowed);Platelets (Plts) ≥ 100 k/mm^3; (2) Hepatic:Bilirubin ≤1.5×upper limit of normal (ULN),Aspartate aminotransferase (AST) ≤2.5 × ULN, ≤ 5 x ULN if liver metastases are present;Alanine aminotransferase (ALT) ≤ 2.5 × ULN, ≤ 5 x ULN if liver metastases are present; (3) Renal:Cr≤ 1.5 x ULN or Ccr≥ 50 mL/min, and Urine dipstick test result show urinary protein < 2+. The urinary protein ≥ 2 + should be 24-hour urine collection and ensure 24 hours urine protein content < 1 g; 8. Patients agreed and have the ability to follow the study plan to be visited, agreed to provide blood specimens in the process of preoperative (within one week) and postoperative (3-4 weeks, 20 weeks and 1 year after surgery) and tumor tissue specimens by operation, and cooperate with other research steps.

Exclusion Criteria:

  1. Second primary malignancy, other than cervical carcinoma in situ after adequate treatment, in situ malignancies or adequately treated basal cell carcinoma of the skin, localized prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery;
  2. Clinical evaluation for patients with inoperable;
  3. A serious uncontrolled medical disorder or active infection that in the investigator's opinion would impair the participant's ability to receive study treatment;
  4. Prior therapy with surgery, chemotherapy, targeted therapy and immunotherapy is not allowed;
  5. Eastern Cooperative Oncology Group performance status(ECOG PS ) ≥2;
  6. A definite clinical active infection, including but not limited to pneumonia;
  7. Other situation the researchers think that doesn't fit into the group.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03337711


Contacts
Contact: Hao Long, Prof +86 20 87343261 longhao@sysucc.org.cn
Contact: Ruping Xing +86 20 87343736 xingrp@sysucc.org.cn

Locations
China, Guangdong
Sun Yat-Sen university cancer center Recruiting
Guangzhou, Guangdong, China, 510000
Contact: Hao Long, Prof    +86 2087343261    longhao@sysucc.org.cn   
Contact: Ruping Xing    +86 2087343736    xingrp@sysucc.org.cn   
Sponsors and Collaborators
Sun Yat-sen University
  More Information

Responsible Party: Hao Long, professor, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT03337711     History of Changes
Other Study ID Numbers: A2017-001
First Submitted: November 6, 2017
First Posted: November 9, 2017
Last Update Posted: November 9, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Hao Long, Sun Yat-sen University:
NSCLC;ctDNA;IIA-IIIA

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases